Overview of Humana’s Q1 2026 Financial Results
Humana delivered a strong but nuanced first-quarter performance in 2026, posting a net income of $1.18 billion. This result marks a modest dip from the $1.24 billion the insurer earned during the same period in 2025. Despite the slight year-over-year decline, total revenue surged to $39.6 billion — up sharply from $32.1 billion in Q1 2025. The company announced these figures on April 29, 2026.
The results reflect both the power of Humana’s Medicare Advantage growth strategy and the real financial pressure stemming from declining CMS star ratings. Together, these forces shaped a quarter defined by revenue momentum on one side and margin headwinds on the other.
Revenue Growth: What’s Driving the Numbers
Medicare Membership Expansion
Humana’s revenue jump was not accidental. Several key factors worked in the insurer’s favor during Q1. First, Medicare membership grew across its core businesses, adding premium volume to the top line. Additionally, per-member premiums rose for both Medicare Advantage (MA) and standalone prescription drug plans, reflecting higher MA benchmark funding from the Centers for Medicare and Medicaid Services (CMS).
Inflation Reduction Act Impact
Another significant driver was the increase in Part D direct subsidies under the Inflation Reduction Act. This policy change provided a meaningful tailwind to Humana’s revenue base, partly offsetting cost pressures elsewhere in the business. Together, these factors propelled the company’s revenue to record levels for a first quarter.
Star Ratings Headwinds and Their Financial Impact
A Dramatic Drop in 4-Star Plans
Not all news from Q1 was positive. Humana faced substantial star ratings-related headwinds that reduced quality bonus payments from CMS. The share of Humana’s MA members enrolled in plans rated 4 stars or higher collapsed to just 25% for the 2025 rating year — down from 94% in 2024. This sharp decline directly diminished bonus payments the company would otherwise have received.
Ongoing Legal Challenge
In response to this setback, Humana appealed a court ruling in November that upheld the lower star ratings. The outcome of that appeal could have significant implications for future quality bonus payments. Consequently, the star ratings issue remains one of the most consequential long-term risks facing the company’s Medicare business.
Benefit Ratio and Membership Guidance
Rising Benefit Ratio
Humana’s benefit ratio — the percentage of premiums paid out as medical claims — reached 89.4% in Q1 2026, up from 87% in Q1 2025. A rising benefit ratio signals higher medical costs relative to premiums collected, which puts downward pressure on margins. However, the company has not wavered on its full-year outlook.
2026 Membership and EPS Guidance Affirmed
Humana reaffirmed its full-year 2026 individual MA membership growth guidance of approximately 25% over 2025 levels, driven by new sales and improved member retention. Furthermore, the company maintained its adjusted full-year earnings per share (EPS) guidance of at least $9. It did revise its GAAP EPS guidance slightly downward — from at least $8.89 to at least $8.36 — reflecting updated cost assumptions.
Insurance Segment Performance
Humana’s insurance segment generated $38.1 billion in revenue for the quarter, compared to $30.9 billion in Q1 2025. Income from operations in this segment reached $1.4 billion, down from $1.6 billion a year ago. The revenue growth reflects solid MA and Part D enrollment gains, while the modest income decline points to higher medical costs and the star ratings impact weighing on margins. Overall, the segment remains the engine of Humana’s business, contributing the overwhelming share of total company revenue.
CenterWell Health Services: Growth and Challenges
Revenue Growth at CenterWell
CenterWell, Humana’s health services segment, posted $6.1 billion in revenue for Q1 2026, up from $5.1 billion in the same period last year. This growth reflects strong primary care expansion and increasing patient volumes across the platform.
Compressed Margins from Acquisitions
Despite the revenue gain, CenterWell’s income from operations fell to $289 million from $392 million in Q1 2025. Its operating cost ratio climbed to 94.5% from 91.1%, driven partly by transaction and integration costs tied to the acquisition of MaxHealth, which closed in February 2026. A previously disclosed headwind from the November 2025 acquisition of The Villages Health also contributed to cost pressure.
Primary Care Patient Growth
CenterWell Senior Primary Care saw impressive growth, adding 110,500 patients — a 22% increase. Of these, 59,000 patients and 54 centers came from the MaxHealth acquisition. As of March 31, 2026, the primary care platform served 601,600 total patients, representing 44% growth year over year. This expansion positions CenterWell as a central pillar of Humana’s value-based care strategy going forward.
Key Takeaways for the Medicare Advantage Market
Humana’s Q1 2026 results offer a clear picture of where the Medicare Advantage market stands today. Revenue growth remains robust, fueled by enrollment gains and favorable policy tailwinds from the Inflation Reduction Act. At the same time, star ratings volatility poses a structural challenge that goes beyond one company — it affects quality incentives across the industry.
Humana’s strong member retention and aggressive primary care expansion through CenterWell signal a long-term commitment to value-based care delivery. Moreover, the outcome of its star ratings appeal could reshape its financial trajectory for 2027 and beyond. For now, the company heads into the remainder of 2026 with affirmed guidance and a growing membership base, even as cost pressures and rating headwinds demand close attention.
